Bank of America Corp DE Acquires 1,586,230 Shares of Haleon PLC Sponsored ADR $HLN

Bank of America Corp DE grew its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 17.0% in the first quarter, Holdings Channel reports. The fund owned 10,934,228 shares of the company’s stock after acquiring an additional 1,586,230 shares during the quarter. Bank of America Corp DE’s holdings in Haleon were worth $109,452,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HLN. Brighton Jones LLC acquired a new position in Haleon during the 4th quarter worth about $187,000. AQR Capital Management LLC raised its position in shares of Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after acquiring an additional 17,720 shares during the last quarter. Focus Partners Wealth raised its position in shares of Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after acquiring an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the period. Finally, CW Advisors LLC lifted its stake in shares of Haleon by 11.6% in the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock worth $260,000 after acquiring an additional 2,601 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.0%

Shares of HLN stock opened at $10.03 on Friday. Haleon PLC Sponsored ADR has a 52-week low of $8.65 and a 52-week high of $11.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The company has a 50-day simple moving average of $9.51 and a two-hundred day simple moving average of $9.85. The company has a market capitalization of $44.16 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 2.01 and a beta of 0.12.

Haleon Cuts Dividend

The business also recently declared a dividend, which will be paid on Thursday, September 17th. Investors of record on Friday, August 14th will be given a dividend of $0.0642 per share. The ex-dividend date is Friday, August 14th. This represents a yield of 127.0%. Haleon’s dividend payout ratio is presently 64.10%.

Analysts Set New Price Targets

A number of analysts have weighed in on HLN shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Zacks Research cut Haleon from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Finally, Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Haleon has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.